Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles.

1. 1
1
2021 © Roots Analysis
x
Tracking the healthcare innovation
C O N F I D E N T I A L | www.rootsanalysis.com
Free
Insights
Peptide Therapeutics Market, 2021-2030
Distribution by Type of Peptide (Small, Medium and Large), Route of Administration (Intravenous, Oral, Subcutaneous,
Topical and Others), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) and Key
Therapeutic Area (Metabolic Diseases, Oncological Diseases, Endocrine Diseases, Gastrointestinal Diseases and Others):
Industry Trends and Global Forecasts, 2021 – 2030

2. 2
2
2021 © Roots Analysis
Our clients are extremely competitive. The confidentiality of companies’ plans and data is obviously critical. Roots Analysis will protect the
confidentiality of all such client information.
Similarly, business research and management consulting is a competitive business. We view our approaches and insights as proprietary
and, therefore, look to our clients and prospective clients to protect Roots Analysis’ interests in our presentations, methodologies and
analytical techniques. Under no circumstances should this material be shared with any third party without our prior written consent.
Copyright © 2021 Roots Analysis Private Ltd.
Note on Confidentiality

3. 3
3
2021 © Roots Analysis
Contents
 Context
 Project Objectives
 Project Approach
 Example Highlights
 Chapter Outlines
 Table of Contents
1
2
3
4
5
6

4. 4
4
2021 © Roots Analysis
Characterized by a rapidly growing pipeline, over 10 product approvals per year, and steady rise in market value, the peptide-
based therapies segment represents one of the fastest growing and major drug classes in the biopharmaceutical industry
Context
Recent and
Upcoming
Trends
Driven by lucrative investments and
involvement of prominent biotech
companies, the market is expected to
witness substantial growth in the
foreseen future
Growing Pipeline of
Peptide Therapeutics
The success of peptide therapeutics is
evident in the fact that there are
multiple blockbuster products in the
market today, causing stakeholders to
continue to invest in R&D in this field
Benefits of Peptide
Therapies
A growing body of evidence supports
the high potency, vast applicability and
therapeutic superiority of peptides over
small molecules and certain complex
biologicals, as well
High Target
Specificity
Peptide-target
interactions are
stronger, involving
robust biochemical
bonds
Improved
Bioavailability
Peptides are more
bioavailable
compared to small
molecule drugs /
larger biologics
Better Safety
Profile
Peptide drugs are
less immunogenic
and are degraded
without forming
toxic metabolites
Invested across 6
years to finance
drug development
efforts in this field
7+
USD
Billion
Involved in
research and
development of
peptide drugs
130+ Players
Inked by various
stakeholders,
between 2015 and
2021
70+ Partnerships
Already available
in markets across
various regions of
the world
65+
Have either been
completed or are
currently underway
/ planned, till date
Presently under
development in the
clinical and
preclinical stages
280+ 1,200+
Pipeline
Candidates
Approved
Products
Clinical
Trials

5. 5
5
2021 © Roots Analysis
A detailed review of the overall market
landscape of peptide-based therapies, featuring
an elaborate list of more than 300 molecules,
and analyses based on a number of relevant
parameters.1
Market
Overview
An in-depth analysis of the investments made at
various stages of development in companies that
are focused in this area, between 2015-2021,
including seed financing, venture capital
financing, IPOs, secondary offerings, debt
financing, grants and other equity offerings.
Funding
Analysis
An elaborate analysis of the players engaged in
the development of peptide therapeutics, along
with information on their year of establishment,
company size and location of headquarters.
Competitive
Landscape
A detailed geographical, clinical trial analysis of
completed, ongoing and planned studies for
numerous peptide drugs, based on various
relevant parameters, such as trial registration
year, trial status, trial phase and geography.
Clinical Trial
Analysis
An insightful summary highlighting the clinical
and commercial attractiveness of pipeline
molecules (phase II and phase III), taking into
consideration company size, development
stage, target population, expected launch year,
dosage frequency and type of peptide.
Clinical/Commercial
Attractiveness
An analysis of the big pharma players engaged
in this domain, featuring a heat map
representation, based on parameters, such as
number of candidates under development,
investments made and partnership activity.
Big Pharma
Initiatives
An analysis of the recent collaborations
(established since 2015) focused on peptide
therapeutics, based on various parameters,
such as type of agreement, scale of operation
and therapeutic area.
Recent
Collaborations
Project Objectives
Roots Analysis has done a detailed report on Peptide Therapeutics covering key aspects of the industry and identifying
future growth opportunities
An informed estimate of the likely evolution of
the peptide therapeutics market, over the period
2021-2030. The report also provides insights on
the likely distribution of the future opportunity
across multiple important market segments.2
Market
Forecast
Note 1: The chapter features a detailed analysis of pipeline molecules, based on several relevant parameters, such as phase of development (marketed, clinical, preclinical and discovery) of pipeline candidates, type of peptide (small,
medium and large), route of administration (intravenous, oral, subcutaneous, topical and others) and key therapeutic area.
Note 2: The projected opportunity has been analyzed across the following segments [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical
regions (North America, Europe, Asia-Pacific and rest of the world) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, gastrointestinal diseases and others)

6. 6
6
2021 © Roots Analysis
Information
Sources
Market Forecast
Outputs
Overall Market Forecast till 2030 is segmented by
 Type of Peptide: Small Peptides, Medium Peptides and Large Peptides
 Route of Administration: Intravenous, Oral, Subcutaneous, Topical and
Others
 Key Geographical Regions: North America, Europe, Asia-Pacific and
Rest of the World
 Therapeutic Area: Metabolic Diseases, Oncological Diseases, Endocrine
Diseases, Gastrointestinal Diseases and Others
Market Insights Industry
Landscape
Key Growth
Drivers
Challenges
Future Trends /
Scenarios
Specific Model
Parameters
Data Triangulation In-house Experts
Industry Stakeholders
(via Primary Research)
Client Feedback
(ongoing pre / post project release)
Project Approach
Historical Revenues
Generated by
Approved Peptides
Competitive
Landscape
Likely Price of
the Therapy
Indication Specific
Adoption Trends
Types of
Peptide
Therapeutic
Area
Geography
Route of
Administration
Secondary Research
Press Releases
Other Analysts’
Opinion Reports
Annual Reports
Industry
Databases
Investor
Presentations
SEC Filings

7. 7
7
2021 © Roots Analysis
Abbreviations: HQ: Headquarters
Note: The regional strength has been estimated using the following formula: Σn*k; where n=number of molecules, k=score based on status of development (discovery=0.5, preclinical=1, phase I=2, phase I/II=2.5, phase II= 3, phase
II/III=3.5, phase III=4, registration=4.5, approved= 5)
Peptide Therapeutics: Development Pipeline
S. No. Drug Name Phase Developer(s) HQ Type of Peptide Number of Amino Acids Route of Administration Target Indication Therapeutic Area
7 ParsabivTM Approved Linear, Small Peptide 7 Intravenous Secondary hyperparathyroidism Endocrine Diseases
19 Vyleesi® Approved Cyclic, Small Peptide 7 Subcutaneous Female sexual dysfunction Others
53 Mycapssa® Approved
63 Rybelsus® Approved
89 Melgain® Approved
98 Tirzepatide Phase III
112 Pegcetacoplan Phase III
139 RGN-259 Phase III
148 Zilucoplan Phase III
150 SP16 Phase I / II
164 SOR-C13 Phase I
168 RGN-352 Phase I
171 Dapiglutide Phase I
206 CB513 Preclinical
221 GC01 Preclinical
231 OFX-514 Preclinical
258 XG-102 Preclinical
262 IK15800 Discovery
285 LAS-103 Discovery
306 PNA-5 Discovery
Example Highlights
With 25 approved drugs and over 280 candidates under development, peptide therapeutics currently represent
one of the fastest growing drug classes, capable of treating a diverse range of diseases
Content Illustrative
(details available upon request)
Information on 300+ peptide-based therapies is available in the report
California: Allysta
Pharmaceuticals,
Company B
Colorado:
Ampio Pharmaceuticals
Arizona: ProNeurogen
Oregon: 13 Therapeutics
Massachusetts: Constant Therapeutics,
Radius Health, Company C
Washington DC: Serpin Pharma
Virginia: TearSolutions
Texas: Pulmotect
Florida: OPKO Health
Illinois: Genus Oncology
Indiana: Eli Lilly
Maryland: Altimmune, MedImmune
Michigan: Diapin Therapeutics
North Carolina: Company D
New Jersey: Company F
New York: iBio, Company G
Belgium: Apitope, Company I
Denmark: Novo Nordisk
France: Sanofi
Germany: Bayer, Company J
Norway: APIM Therapeutics
Sweden: Follicum, Company K
Switzerland: Biolingus, Polyphor,
Israel: BioLineRx, Company L
India: Issar Pharmaceuticals
Australia: Clinuvel
Pharmaceuticals,
Company P
10 ≤ Score < 25
0 < Score < 10
25 ≤ Score < 50
Score ≥ 50
South Korea: Peptron, Company O
Canada: Arch Biopartners, Company A
Connecticut: Cara Therapeutics
Delaware: CureDM
Louisiana: Esperance Pharmaceuticals,
Minnesota: Gila Therapeutics
Pennsylvania: Amyndas
Pharmaceuticals,
Company B
South Carolina:
FirstString Research
Austria: Apeptico
UK:
GlaxoSmithKline,
Company H
Spain: PharmaMar
The Netherlands:
Zealand Pharma
China: Frontier Biotechnologies, Company N
Japan: Takeda, Company M
Regional Strength
New Zealand: Curonz
Regional Landscape of Developers1

8. 8
8
2021 © Roots Analysis
The pipeline features a variety of peptides being evaluated for delivery via different routes, and mostly intended
for treating metabolic and oncological disorders
8.0%
33.8%
12.2%
4.5%
23.3%
0.3%
7.3%
2.1%
8.4%
Discovery Preclinical Phase I
Phase I / II Phase II Phase II / III
Phase III Registration Approved
Peptide Therapeutics: Pipeline
Distribution by Phase of Development
The early stage peptide therapeutics pipeline is substantial
and growing, indicating the rising research interest in this
field; leading innovators in the domain primarily include
well-established and small players
Example Highlights
Abbreviations: RoA: Route of Administration, TA: Therapeutic Area, MD- Metabolic Diseases, OD- Oncological Diseases, AD- Autoimmune Diseases, CD- Cardiovascular Diseases, GD- Genetic Diseases, OPD- Ophthalmology Diseases, DC-
Discovery, PC- Preclinical, RG- Registration, AP- Approved
Note 1: Therapies for which information on the type of peptide was available have been included in this representation
Note 2: Therapies for which information on the phase, route of administration and therapeutic area was available, have been included in this representation
.
Peptide Therapeutics: Grid Analysis
Distribution by Phase, RoA and TA 2
Prominent examples of approved peptides, intended for the
treatment of a wide range of diseases, and administered
using the subcutaneous route include (in alphabetical
order) Ozempic®, Tymlos ®, Vyleesi ® and Zegalogue®
GD
CD
AD
OD
MD
OPD
DC I II
I / II II / III
PC RG
III AP
2 3
9
1
33
10
21
20 17
7
7
10
13
28
49
Subcutaneous Intravenous Oral Topical
Peptide Therapeutics: Pipeline
Distribution by Type of Peptide1
Close to 76% therapeutic peptides consist of short amino
acid chains, owing to advantages, such as faster
production, better selectivity for a specific target and
minimal toxicity
121
36
2
Types of Peptide
Small Peptides Medium Peptides Large Peptides
Key Players

9. 9
9
2021 © Roots Analysis
Product 3
In lieu of the growing competition from several viable candidate therapies, innovators are putting in significant
efforts to ensure that their proprietary offerings are both clinically and commercially differentiated
Peptide Therapeutics: Late-Stage Pipeline
Clinical Commercial Attractiveness Analysis1
An in-depth analysis of the late-stage peptide
drugs for metabolic diseases, ophthalmic
diseases, genetic diseases, oncological
diseases and other diseases, is available in
the report titled “Peptide Therapeutics
Market, 2021-2030”
Commercial Attractiveness (on the Y-
axis) represents the potential of the
molecule after it is approved for marketing.
This parameter is calculated as Σn*i/Σn,
where “i” are the parameters (developer
size, development stage, location of clinical
trials and expected launch year) and “n” is
the weight for each parameter
Clinical Attractiveness
(on the X-axis) represents the potential of
the molecule in terms of its safety, efficacy
and other clinical aspects. This parameter is
calculated as Σn*i/Σn, where “i” are the
parameters (number of subjects involved in
clinical trial, route of administration, dosage
frequency, type of peptide) and “n” is the
weight for each parameter
Example Highlights
Therapeutic
Area Hematological Diseases
Autoimmune Diseases
Metabolic Diseases
Infectious Diseases
Oncological Diseases
Inflammatory Diseases
Ophthalmic Diseases
CNS Diseases Endocrine Diseases
Genetic Diseases
Gastrointestinal Diseases
Others
Commercial
Attractiveness
Clinical Attractiveness
Product 19
Product 21
Product 20
Product 26
Product 17
Product 16
Product 18
Ozempic ®
Lupuzor ®
Product 22
Product 23
Rybelsus ®
Product 1
Product 7
Product 9
Ninlaro ®
Product 11
Pegcetacoplan Product 2
Product 24
Glepaglutide
Product 28
Content Illustrative
(details available upon request)
Product 6
Product 12
Product 13
Product 25
Product 27

10. 10
10
2021 © Roots Analysis
Over 1,200 peptide focused clinical trials have been registered across the world; presently, most of these studies
are evaluating product candidates intended for the treatment of metabolic diseases
North America Europe
United States XX
Canada 207
Rest of North
America
XX
169
France
196
UK
South Africa 73
RoW
Asia-Pacific
Peptide Therapeutics Clinical Research Landscape
Geographical Distribution of Clinical Trials1, 2
XX
Spain
XX
Rest of
Europe
84 Korea
XX Rest of Asia-Pacific
XX Australia
231 India
Rest of RoW XX
Example Highlights
Note 1: Clinical trials for which information on site location was available have been included in this representation
Note 2: The trials that were / are being conducted across more than one location have been counted multiple times in this representation
Content Illustrative
(details available upon request)
38
129
199
818
Not yet recruiting
Active, not recruiting
Active
Completed
Distribution by Trial Status
5
240
54
334
15
428
110
Early Phase I
Phase I
Phase I / II
Phase II
Phase II / III
Phase III
Phase IV
Distribution by Trial Phase

11. 11
11
2021 © Roots Analysis
2015
2016
2017
2018
2019
2020
2021
(till Feb)
The growing interest in this field is also evident in the increase in recent partnership activity; majority of the deals
established since 2015 were observed to be focused on technology and / or product licensing
Partnerships and Collaborations
Distribution by Year and Scale of Operation
Between 2015 and 2020, the partnership activity in this
domain increased at a CAGR of 15%; licensing agreements
(28%) emerged as the most popular type of partnership
Partnerships and Collaborations
Distribution by Type of Partnership and TA1, 2
In 2020, over 42% peptide-focused deals were signed for
infectious diseases owing to the surge in demand for
biologics amidst the COVID-19 pandemic
Example Highlights
Partnerships and Collaborations
Distribution by RoA and Geography
Majority of the partnerships across various routes of
administration have been inked by companies based in
North America (52%), followed by Europe (46%)
8% 15% 21% 48% 8%
Industry
Average
Legend
Percentage smaller than industry average
Gastro-
Intestinal
Diseases
Endocrine
Diseases
Infectious
Diseases
Oncological
Diseases
Respiratory
Diseases
Clinical Trial
Agreements
Distribution
Agreements
Licensing
Agreements
Product
DA
Product D&C
Agreements
Services
Agreements
Percentage greater than industry average
Relative Distribution of Partnerships
North America Europe
Legend Asia-Pacific
XX%
XX%
XX%
25%
XX%
XX%
XX% XX% XX% 73%
XX% XX% 25% XX%
14% XX% XX% 57%
XX% XX% XX%
XX% XX% XX%
XX% XX% 50% XX%
XX%
33%
Relative Distribution of Partnerships
20%
14%
11%
10%
16%
6%
23%
43%
57%
Intravenous
38%
38%
23%
Subcutaneous
71%
29%
Oral
40%
60%
Inhaled
Preclinical Clinical Commercial
Abbreviations: TA: Therapeutic Area, DA- Development Agreements, D&C: Development and Commercialization, RoA: Route of Administration
Note 1: Therapeutic areas presented here were shortlisted based on the number of associated collaborations inked during the period 2015-2021, specifically for peptide design and development
Note 2: The percentages mentioned in the figure are indicative of the share of deals inked with respect to the type of partnership and therapeutic area

12. 12
12
2021 © Roots Analysis
91% 9%
US Canada
92% 8%
Israel South Korea
Funding and Investments
Distribution of Amount Invested by Geography
Foreseeing promising returns, many public and private sector investors have invested over USD 7 billion, across
more than 200 instances, in the period between 2015 and 2021
Funding and Investments
Distribution by Year, Amount Invested and Type of Funding
Amount
Invested
(in
USD
million)
Seed Grants
Other Equity
Venture Capital IPO Secondary Offerings
Private Equity Debt
Legend
14%
4%
6%
15%
61%
Example Highlights
Asia-Pacific
North America
Key Players
Content Illustrative
(details available upon request)
Europe
88% 10% 2%
North America Europe Asia-Pacific
39.6% 19.7% 12.7% 10.9% 6.1% 5.9% 5.0%
France UK Belgium Switzerland Austria Germany Rest of Europe
>100
75-100
50-75
25-50
<25
2015 2016 2017 2018 2019 2020 2021

13. 13
13
2021 © Roots Analysis
P1
P2
P3
P4
P5
Big Pharma Initiatives
Capability Benchmarking: 5-D Spider Web Analysis
Partnerships &
Collaborations
Big Pharma Company
Company 1
Company 3
Company 6
Company 8
Company 9
Company 11
Company 12
Company 13
Company 15
Company 16
Funding &
Investments
Late Stage
Pipeline
Clinical
Trials
Score Meter
Big Pharma Initiatives
Competitive Benchmarking
Example Highlights
In order to tap into the lucrative opportunity in this rapidly growing market, several big pharma players have
undertaken initiatives, ranging from proprietary product development to strategic investments, in this direction
Number of Initiatives
Low High
Note: Detailed list of peptide focused initiatives undertaken by 15 big pharma players is available in the report titled “Peptide Therapeutics Market, 2021-2030”
Company 1 Company 2
P1: Partnerships & Collaborations P4: LateStage Pipeline
P2: Funding & Investments P5: Number of Clinical Trials
P3: Early Stage Pipeline
Content Illustrative
(details available upon request)
Big Pharmaceutical Players Actively Engaged in the Peptide Therapeutics Domain
15
Big Pharma Players
P1
P2
P3
P4
P5
Company 3 Company 4
P1
P2
P3
P4
P5
P1
P2
P3
P4
P5

14. 14
14
2021 © Roots Analysis
With a promising development pipeline and encouraging clinical outcomes, the peptide therapeutics market is
anticipated to grow at an annualized rate of ~11%, over the next decade
Example Highlights
USD Billion
Peptide Therapeutics Market
Distribution by Therapeutic Area1,4
Additional
potential
till
2030
Therapeutic
Area
2
USD XX BN
USD XX BN
USD XX BN
USD XX BN
USD XX BN
Likely
market
size
in
2021
Therapeutic
Area
3
Therapeutic
Area
4
Therapeutic
Area
5
Metabolic
Diseases
Peptide Therapeutics Market
Distribution by Geography1,5
Future
Market
Share
Current Market Share
Note: The size of the bubble represents the CAGR
USD Billion
North America
Region 2
Region 4
Region 3
Note 1: Illustrations are not as per actual scale
Note 2: The Peptide Therapeutics Market, 2021-2030 takes into consideration the following types of peptides: Small Peptides, Medium Peptides and Large Peptides
Note 3: The Peptide Therapeutics Market, 2021-2030 takes into consideration the following routes of administration: Subcutaneous, Oral, Intravenous, Topical and Nasal
Note 4: The Peptide Therapeutics Market, 2021-2030 takes into consideration the following therapeutic areas: Metabolic Diseases, Oncological Diseases, Endocrine Diseases, Digestive and Gastrointestinal Diseases and Others
Note 5: The Peptide Therapeutics Market, 2021-2030 takes into consideration the following geographical regions: North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and Rest of the World
XX
XX
XX
XX
XX
XX
2021 2030
Distribution by Type of Peptide1,2
USD Billion
Distribution by Route of Administration1,3
USD Billion
Small Peptides
Medium Peptides
Large Peptides
Subcutaneous
(XX%)
RoA 2
(XX%)
RoA 3
(XX%)
RoA 4
(XX%)
RoA
5
(XX%)

15. 15
15
2021 © Roots Analysis
Get in touch to know more!
sales@rootsanalysis.com
Report Details
Product Code: RA100268
Pages: 250
Publication Date: 26 April 2021
Number of Tables: 109
Number of Figures: 127
Pricing Details
Single-User License: USD 5,499
Site License: USD 7,999
Enterprise License: USD 15,999

16. 16
16
2021 © Roots Analysis
LICENSE TYPE (tick one)
Report Title: RA100268: Peptide Therapeutics Market, 2021-2030
USD ($) EUR (€) GBP (£)
Single User License $5,499 €4,799 £4,249
Site License $7,999 €7,049 £6,199
Enterprise License $15,999 €14,099 £12,399
CUSTOMER DETAILS
Name: Email:
Job Title: Company:
Address:
City: Country:
ZIP Code: Phone:
PAYMENT DETAILS
Select preferred currency option
USD ($)
EUR (€)
GBP (£)
Please invoice my company for _______________
PAYMENT AUTHORIZATION
Sign below to authorize the payment
_____________________________________________________ Date ________________
NOTE
The prices mentioned on this form and on the website are inclusive of all
taxes. You can also buy the reports online by visiting the page
www.rootsanalysis.com/reports. For any queries, write to us at
sales@rootsanalysis.com. Please note that by ordering from Roots
Analysis Private Limited, you are agreeing to the Terms and Conditions at
www.rootsanalysis.com/terms
Purchase Your Copy Today!
Scan and email this form to sales@rootsanalysis.com

17. 17
17
2021 © Roots Analysis
Chapter Outlines (1/2)
 Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the peptide therapeutics market and its likely evolution in the short to mid term and
long term.
 Chapter 3 provides a general overview of peptide therapeutics, including a discussion on their structure, classification and types of modifications. In addition, the chapter includes information on the historical
evolution of peptides. Further, it features a brief overview of the design and development of therapeutic peptides, as well as a comparison between traditional and novel peptide technologies, along with the
advantages and disadvantages associated with peptide-based therapies. Furthermore, the chapter presents details on the applications of peptide drugs along with providing an overview of the upcoming future
trends, which, we believe, are likely to influence the growth of the peptide therapeutics market.
 Chapter 4 includes information on over 300 peptide-based therapies that are currently approved or are in different stages of development. It features a detailed analysis of pipeline molecules, based on several
relevant parameters, such as phase of development (marketed, clinical, preclinical and discovery), type of peptide (small, medium and large), number of amino acids, route of administration (intravenous, oral,
subcutaneous, topical and others) and key therapeutic area. Further, we have presented a grid analysis of peptide therapeutics based on phase of development, route of administration and key therapeutic area.
 Chapter 5 provides a detailed review of the players engaged in the development of peptide drugs, along with information on their year of establishment, company size, location of headquarters. Further, we have
presented a logo landscape of peptide developers in North America, Europe and the Asia-Pacific region on the basis of phase of development and key players engaged in this domain. In addition, we have
presented a heat map analysis of developers on the basis of company size, phase of development and geography.
 Chapter 6 provides detailed profiles of prominent players engaged in development of peptide drugs. Each company profile features a brief overview of the company, financial details / information (if available),
pipeline details, recent developments and an informed future outlook.
 Chapter 7 highlights top big biopharma players engaged in the field of therapeutic peptides, featuring a heat map analysis based on several parameters, including number of amino acids, route of administration
and therapeutic area.
 Chapter 8 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description on the various types of
partnership models (which include acquisition-based agreements, clinical trial agreements, distribution agreements, joint ventures, licensing agreements, manufacturing agreements, product-based agreements,
R&D agreements and services agreements) that have been adopted by stakeholders in this domain. It also consists of a schematic representation showcasing the players that have established the maximum
number of alliances related to the peptide therapeutics. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across
different continents.
 Chapter 9 presents details on various funding instances, investments and grants reported within the peptide therapeutics domain. The chapter includes information on various types of investments (such as venture
capital financing, debt financing, grants, capital raised from IPO and subsequent offerings) received by the companies between 2015 and 2021, highlighting the growing interest of the venture capital community
and other strategic investors in this market.
 Chapter 10 provides a detailed analysis of completed, ongoing, and planned clinical studies of various therapeutic peptides, highlighting prevalent trends across various relevant parameters, such as trial
registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key
geographical regions.
 Chapter 11 features an analysis of the clinical and commercial attractiveness of the peptide drugs designed for the treatment of various types of diseases. In the chapter, each of the drugs / drug candidates were
plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes. The clinical attractiveness of a drug was determined based on the sample size of the
associated trial, route of administration, therapy type and dosing frequency. The commercial attractiveness of a drug was determined based on the size of target patient population, expected launch date and
company size of the developer company.
 Chapter 12 is a case study focused on the role of service providers that operate within the peptide therapeutics market and captures information on the various CROs, CMOs and custom peptide manufacturers
that are actively involved in this segment of the peptide therapeutics market. In addition, the chapter includes the advantages and challenges associated with outsourcing,

18. 18
18
2021 © Roots Analysis
Chapter Outlines (2/2)
 along with the key parameters that need to be considered while selecting a service provider.
 Chapter 13 is a case study presenting the key characteristics of novel peptides drugs, along with information on the applications, advantages and key challenges involved in their development processes.
 Chapter 14 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. It also includes future sales projections of peptide-based therapies that are either
marketed or in advanced stages of clinical development (phase II/III and above). The chapter also presents a detailed market segmentation on the basis of [A] type of peptide (small, medium and large), [B] route of
administration (intravenous, oral, subcutaneous, topical and others), and [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases,
oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across
different therapeutic areas.
 Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the peptide therapeutics market, based on the research and analysis described in the previous
chapters.
 Chapter 16 is an appendix that provides the list of approved peptide therapeutics during the period 2000 and 2012.
 Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
 Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

19. 19
19
2021 © Roots Analysis
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Peptides
3.3. Classification of Peptides
3.4. Modification of Peptides
3.4.1. N-Terminal Modifications
3.4.2. Internal Modifications
3.4.3. C-Terminal Modifications
3.4.4. Other Modifications
3.5. Evolution of Peptide Therapeutics
3.6. Design and Development of Peptide Therapeutics
3.6.1. Traditional versus Novel Peptide Technologies
3.7. Advantages and Disadvantages of Peptide Therapeutics
3.8. Applications of Peptide Therapeutics
3.9. Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Peptide Therapeutics: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Peptide
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Phase of Development and Route of Administration
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Phase of Development and Therapeutic Area
4.2.7. Analysis by Route of Administration and Therapeutic Area
4.2.8. Analysis by Phase of Development, Route of Administration and
Therapeutic Area (Grid Representation)
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Peptide Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography
5.2.4. Analysis by Phase of Development and Geography (Logo Landscape)
5.2.5.Key Players: Analysis by Number of Product Candidates
5.3.Analysis by Company Size, Key Therapeutic Area and Geography (Heat
Map Representation)
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Apellis Pharmaceuticals
6.2.1. Company Overview
6.2.2 Pipeline Details
6.2.2. Recent Developments and Future Outlook
6.3. BioLineRx
6.3.1. Company Overview
6.3.2. Pipeline Details
6.3.3. Recent Developments and Future Outlook
6.4. Eli Lilly
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Details
6.4.4. Recent Developments and Future Outlook
6.5. FirstString Research
6.5.1. Company Overview
6.5.2. Pipeline Details
6.5.3. Recent Developments and Future Outlook
6.6. Novo Nordisk
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Details
6.6.4. Recent Developments and Future Outlook
6.7. Palatin Technologies
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Details
6.7.4. Recent Developments and Future Outlook
6.8. RegeneRx Biopharmaceuticals
6.8.1. Company Overview
6.8.2. Pipeline Details
6.8.3. Recent Developments and Future Outlook
6.9. Stealth BioTherapeutics
6.9.1. Company Overview
6.9.2. Pipeline Details
6.9.3. Recent Developments and Future Outlook
6.10. Takeda
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Details
6.10.4. Recent Developments and Future Outlook
6.11. Zealand Pharma
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Details
6.11.4. Recent Developments and Future Outlook
7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA
PLAYERS
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused
Initiatives
7.2.1. Analysis by Number of Amino Acids
7.2.2. Analysis by Route of Administration
7.2.3. Analysis by Therapeutic Area
7.3. Benchmark Analysis of Key Parameters
7.3.1. Spider Web Analysis: Pipeline Strength
7.3.2. Spider Web Analysis: Partnerships and Collaborations
7.3.3. Spider Web Analysis: Funding and Investments
7.3.4. Spider Web Analysis: Clinical Trials
7.4. Benchmark Analysis of Big Pharmaceutical Players
7.4.1. Spider Web Analysis: Novo Nordisk
7.4.2. Spider Web Analysis: Amgen
7.4.3. Spider Web Analysis: Takeda
7.4.4. Spider Web Analysis: Eli Lilly
7.4.5. Spider Web Analysis: Johnson and Johnson
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
Table of Contents (1/3)

20. 20
20
2021 © Roots Analysis
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Type of Partnership and Focus Area
8.3.6. Analysis by Type of Peptide
8.3.7. Analysis by Route of Administration
8.3.8. Analysis by Route of Administration and Geography
8.3.9. Analysis by Type of Partnership and Phase of Development
8.3.10. Analysis by Therapeutic Area
8.3.11. Analysis by Type of Partnership and Therapeutic Area
8.4. Most Active Players: Analysis by Number of Partnerships
8.5. Regional Analysis
8.5.1. Intracontinental and Intercontinental Agreements
8.5.2. Local and International Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Peptide Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Year and Type of Funding
9.3.5. Analysis of Amount Invested by Geography
9.3.6. Most Active Players: Analysis by Number of Funding Instances and
Amount Invested
9.3.7. Key Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Phase of Development
9.3.9. Analysis by Therapeutic Area
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Peptide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Recruitment Status
10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.6. Analysis by Study Design
10.3.7. Analysis by Type of Sponsor / Collaborator
10.3.8. Most Active Players: Analysis by Number of Registered Trials
10.3.9. Emerging Focus Area
10.3.10. Analysis by Therapeutic Area
10.3.11. Geographical Analysis by Number of Registered Trials
10.3.12. Geographical Analysis by Enrolled Patient Population
11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.2.1. Assumptions and Key Parameters
11.3. Affiliated Insights
11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune
Diseases
11.3.2. Clinical and Commercial Attractiveness Analysis: Central Nervous
System (CNS) Diseases
11.3.3. Clinical and Commercial Attractiveness Analysis: Endocrine
Diseases
11.3.4. Clinical and Commercial Attractiveness Analysis: Gastrointestinal
Diseases
11.3.5. Clinical and Commercial Attractiveness Analysis: Genetic Diseases
11.3.6. Clinical and Commercial Attractiveness Analysis: Hematological
Diseases
11.3.7. Clinical and Commercial Attractiveness Analysis: Infectious Diseases
11.3.8. Clinical and Commercial Attractiveness Analysis: Inflammatory
Diseases
11.3.9. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases
11.3.10. Clinical and Commercial Attractiveness Analysis: Oncological
Diseases
11.3.11. Clinical and Commercial Attractiveness Analysis: Ophthalmic
Diseases
11.3.12. Clinical and Commercial Attractiveness Analysis: Other Diseases
12. CASE STUDY: CONTRACT SERVICES LANDSCAPE
12.1. Chapter Overview
12.1.1. Chapter Overview
12.2. Role of Service Providers
12.2.1. List of Peptide CROs
12.2.2. List of Platform Providers
12.2.3. List of Peptide CMOs
12.2.3.1. List of Custom Peptide Manufacturers
12.3. Advantages of Outsourcing
12.4. Risks and Challenges Associated with Outsourcing
13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
13.1. Chapter Overview
13.2. Overview of Novel Peptide Therapeutics
13.3. Advantages and Applications of Novel Peptide Therapeutics
13.4. Key Challenges Associated with Novel Peptide Therapeutics
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global Peptide Therapeutics Market, 2021-2030
14.4.1. Global Peptide Therapeutics Market, 2021-2030: Distribution by
Type of Peptide
14.4.2. Peptide Therapeutics Market, 2021-2030: Distribution by Number of
Amino Acids
14.4.3. Peptide Therapeutics Market, 2021-2030: Distribution by Route of
Administration
14.4.4. Peptide Therapeutics Market, 2021-2030: Distribution by Geography
14.4.5. Peptide Therapeutics Market, 2021-2030: Distribution by Key
Therapeutic Area
14.5. Autoimmune Diseases
14.5.1. Value Creation Analysis
14.5.2. Sales Forecast for Approved Peptide Therapeutics
14.5.2.1. Tymlos ®
14.5.3. Sales Forecast for Clinical Peptide Therapeutics
14.5.3.1. Ampion / DMI 9523
14.5.3.2. TBRIA
14.6. Cardiovascular Diseases
14.6.1. Value Creation Analysis
14.6.2. Sales Forecast for Approved Peptide Therapeutics
14.6.2.1. Giapreza ®
14.7. CNS Diseases
14.7.1. Value Creation Analysis
14.7.2. Sales Forecast for Clinical Peptide Therapeutics
14.7.2.1. Nerinitide
14.7.2.2. Rybelsus ®
14.8. Dermatological Diseases
14.8.1. Value Creation Analysis
14.8.2. Sales Forecast for Approved Peptide Therapeutics
14.8.2.1. Melgain
14.9. Endocrine Diseases
14.9.1. Value Creation Analysis
14.9.2. Sales Forecast for Approved Peptide Therapeutics
14.9.2.1. Parsabiv ®
14.9.2.2. Lupykins
Table of Contents (2/3)

21. 21
21
2021 © Roots Analysis
14.9.3. Sales Forecast for Clinical Peptide Therapeutics
14.9.3.1. Difelikefalin / KORSUVA / Oral CR845
14.10. Gastrointestinal Diseases
14.10.1. Value Creation Analysis
14.10.2. Sales Forecast for Approved Peptide Therapeutics
14.10.2.1. Gattex ®
14.10.2.2. Trulance ®
14.10.3. Sales Forecast for Clinical Peptide Therapeutics
14.10.3.1. Glepaglutide / ZP1848
14.10.3.2. Larazotide / INN-202
14.11. Genetic Diseases
14.11.1. Value Creation Analysis
14.11.2. Sales Forecast for Approved Peptide Therapeutics
14.11.2.1. Scenesse ®
14.11.3. Sales Forecast for Clinical Peptide Therapeutics
14.11.3.1. Elamipretide / MTP-131
14.11.3.2. Ninlaro ®
14.11.3.3. Vosoritide / BMN 111
14.11.3.4. Zilucoplan / RA101495
14.12. Hematological Diseases
14.12.1. Value Creation Analysis
14.12.2. Sales Forecast for Clinical Peptide Therapeutics
14.12.2.1. Pegcetacoplan / APL-2
14.13. Infectious Diseases
14.13.1. Value Creation Analysis
14.13.2. Sales Forecast for Approved Peptide Therapeutics
14.13.2.1. Solnatide
14.13.3. Sales Forecast for Clinical Peptide Therapeutics
14.13.3.1. Aikening / Albuvirtide
14.13.3.2. Reltecimod
14.14. Inflammatory Diseases
14.14.1. Value Creation Analysis
14.14.2. Sales Forecast for Clinical Peptide Therapeutics
14.14.2.1. Lupuzor
14.15. Metabolic Diseases
14.15.1. Value Creation Analysis
14.15.2. Sales Forecast for Approved Peptide Therapeutics
14.15.2.1. Adlyxin ®
14.15.2.6. Imcivree ™
14.15.2.3. Mycapssa ®
14.15.2.5. Ozempic ®
14.15.2.4. Rybelsus ®
14.15.2.7. Tanzeum ®
14.15.2.8. Tresiba ®
14.15.2.2. Trulicity ®
14.15.2.10. Zegalogue ®
14.15.3. Sales Forecast for Clinical Peptide Therapeutics
14.15.3.1. Imcivree ™
14.15.3.2. Ozempic
14.15.3.3. Tirzepatide / LY3298176
14.16. Oncological Diseases
14.16.1. Value Creation Analysis
14.16.2. Sales Forecast for Approved Peptide Therapeutics
14.16.2.1. Aplidin ®
14.16.2.2. Lupron ®
14.16.2.3. Lutathera ®
14.16.2.4. Ninlaro ®
14.16.3. Sales Forecast for Clinical Peptide Therapeutics
14.16.3.1. Balixafortide / POL6326
14.16.3.2. Dusquetide / SGX942
14.16.3.3. Motixafortide / BL-8040
14.17. Ophthalmic Diseases
14.17.1. Value Creation Analysis
14.17.2. Sales Forecast for Clinical Peptide Therapeutics
14.17.2.1. RGN-259 / GBT-201
14.17.2.2. Pegcetacoplan / APL-2
14.17.2.3. XG-102
14.19. Other Diseases
14.19.1. Value Creation Analysis
14.19.2. Sales Forecast for Approved Peptide Therapeutics
14.19.2.1. Lupron ®
14.19.2.2. Vyleesi ™
14.19.2.3. Xylentra ™
14.19.3. Sales Forecast for Clinical Peptide Therapeutics
14.19.3.1. BP-101
14.19.3.2. Granexin
14.19.3.3. Ensereptide / PXL01
15. CONCLUDING REMARKS
15.1. Chapter Overview
16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS (2000-
2012)
17. APPENDIX II: TABULATED DATA
18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS
Table of Contents (3/3)

22. 22
22
2021 © Roots Analysis
List of Figures (1/2)
Figure 3.1 Peptide Modification Techniques
Figure 3.2 Historical Timeline of Peptide Therapeutics
Figure 4.1 Peptide Therapeutics: Distribution by Phase of Development
Figure 4.2 Peptide Therapeutics: Distribution by Type of Peptide
Figure 4.3 Peptide Therapeutics: Distribution by Route of Administration
Figure 4.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
Figure 4.5 Peptide Therapeutics: Distribution by Therapeutic Area
Figure 4.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.7 Peptide Therapeutics: Distribution by Route of Administration and Key Therapeutic Area
Figure 4.8 Grid Representation: Distribution by Phase of Development, Route of Administration and Key Therapeutic
Area
Figure 5.1 Peptide Therapeutics Developers: Distribution by Year of Establishment
Figure 5.2 Peptide Therapeutics Developers: Distribution by Company Size
Figure 5.3 Peptide Therapeutics Developers: Distribution by Geography
Figure 5.4 Regional Landscape: Distribution of Peptide Therapeutics Developers by Phase of Development and
Geography
Figure 5.5 Peptide Therapeutics Developers: Key Players
Figure 5.6 Peptide Therapeutics Developers: Distribution by Key Players and Phase of Development
Figure 5.7 Heat Map Representation: Distribution by Company Size, Key Therapeutic Area and Geography
Figure 6.1 Eli Lilly: Annual Revenues, 2015-2020 (USD Million)
Figure 6.2 Novo Nordisk: Annual Revenues, 2015-2020 (DKK Million)
Figure 6.3 Palatin Technologies: Annual Revenues, 2015-2020 (USD Million)
Figure 6.4 Takeda: Annual Revenues, 2015-2020 (JPY Million)
Figure 6.5 Zealand Pharma: Annual Revenues, 2015-2020 (DKK Million)
Figure 7.1 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 7.2 Big Pharma Players: Distribution by Number of Amino Acids
Figure 7.3 Big Pharma Players: Distribution by Route of Administration
Figure 7.4 Big Pharma Players: Distribution by Therapeutic Area
Figure 7.5 Spider Web Analysis: Pipeline Strength
Figure 7.6 Spider Web Analysis: Partnerships and Collaborations
Figure 7.7 Partnerships and Collaborations: Distribution by Year and Type of Partnership Undertaken by Big Pharma
Players
Figure 7.8 Spider Web Analysis: Funding and Investments
Figure 7.9 Spider Web Analysis: Clinical Trials
Figure 7.10 Spider Web Analysis: Novo Nordisk
Figure 7.11 Spider Web Analysis: Amgen
Figure 7.12 Spider Web Analysis: Takeda
Figure 7.13 Spider Web Analysis: Eli Lilly
Figure 7.14 Spider Web Analysis: Johnson and Johnson
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Peptide
Figure 8.7 Partnerships and Collaborations: Distribution by Route of Administration
Figure 8.8 Partnerships and Collaborations: Distribution by Route of Administration and Geography
Figure 8.9 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development
Figure 8.10 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.11 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 8.12 Most Active Players: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.14 Partnerships and Collaborations: Local and International Agreements
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2015-2021
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2015-2021 (USD
Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2021
Figure 9.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2015-2021
(USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2015-2021
Figure 9.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2015-
2021 (USD Million)
Figure 9.7 Funding and Investment Analysis: Summary of Investments, 2015-2021 (USD Million)
Figure 9.8 Funding and Investment Analysis: Distribution by Geography
Figure 9.9 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 9.10 Most Active Players: Distribution by Number of Funding Instances
Figure 9.11 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.12 Funding and Investment Analysis:* Distribution by Type of Investors
Figure 9.13 Funding and Investment Analysis: Distribution by Leading Investors
Figure 9.13 Funding and Investment Analysis: Distribution of Instances by Phase of Development
Figure 9.14 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1 Clinical Trial Analysis: Scope and Methodology
Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2000-2021
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre 2000-2021
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
Figure 10.10 Clinical Trial Analysis: Emerging Focus Area
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 11.1 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Autoimmune Diseases
Figure 11.2 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: CNS Diseases
Figure 11.3 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Endocrine Diseases
Figure 11.4 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Gastrointestinal Diseases

23. 23
23
2021 © Roots Analysis
List of Figures (2/2)
Figure 11.5 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Genetic Diseases
Figure 11.6 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Hematological Diseases
Figure 11.7 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Infectious Diseases
Figure 11.8 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Inflammatory Diseases
Figure 11.9 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Metabolic Diseases
Figure 11.10 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Oncological Diseases
Figure 11.11 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Ophthalmic Diseases
Figure 11.12 Clinical and Commercial Attractiveness Analysis: Phase III Molecules: Other Diseases
Figure 14.1 Global Peptide Therapeutics Market, 2021-2030 (USD Billion)
Figure 14.2 Peptide Therapeutics Market: Distribution by Type of Peptide, 2021-2030
Figure 14.3 Peptide Therapeutics Market: Distribution by Route of Administration, 2021-2030
Figure 14.4 Peptide Therapeutics Market: Distribution by Geography, 2021-2030
Figure 14.5 Peptide Therapeutics Market: Distribution by Key Therapeutic Area, 2021-2030
Figure 14.6 Peptide Therapeutics Market for Autoimmune Diseases, 2021-2030 (USD Billion)
Figure 14.7 Peptide Therapeutics Market for Cardiovascular Diseases, 2021-2030 (USD Billion)
Figure 14.8 Peptide Therapeutics Market for CNS Diseases, 2021-2030 (USD Billion)
Figure 14.9 Peptide Therapeutics Market for Dermatological Diseases, 2021-2030 (USD Billion)
Figure 14.10 Peptide Therapeutics Market for Endocrine Diseases, 2021-2030 (USD Billion)
Figure 14.11 Peptide Therapeutics Market for Gastrointestinal Diseases, 2021-2030 (USD Billion)
Figure 14.12 Peptide Therapeutics Market for Genetic Diseases, 2021-2030 (USD Billion)
Figure 14.13 Peptide Therapeutics Market for Hematological Diseases, 2021-2030 (USD Billion)
Figure 14.14 Peptide Therapeutics Market for Infectious Diseases, 2021-2030 (USD Billion)
Figure 14.15 Peptide Therapeutics Market for Inflammatory Diseases, 2021-2030 (USD Billion)
Figure 14.16 Peptide Therapeutics Market for Metabolic Diseases, 2021-2030 (USD Billion)
Figure 14.17 Peptide Therapeutics Market for Oncological Diseases, 2021-2030 (USD Billion)
Figure 14.18 Peptide Therapeutics Market for Ophthalmic Diseases, 2021-2030 (USD Billion)
Figure 14.19 Peptide Therapeutics Market for Other Diseases, 2021-2030 (USD Billion)

24. 24
24
2021 © Roots Analysis
List of Tables (1/2)
Table 4.1 Peptide Therapeutics: Development Pipeline
Table 5.1 Peptide Therapeutics: List of Drug Developers
Table 6.1 Apellis Pharmaceuticals: Key Highlights
Table 6.2 Apellis Pharmaceuticals: Peptide-based Drugs Portfolio
Table 6.3 Apellis Pharmaceuticals: Recent Developments and Future Outlook
Table 6.4 BioLineRx: Key Highlights
Table 6.5 BioLineRx: Peptide-based Drugs Portfolio
Table 6.6 Eli Lilly: Key Highlights
Table 6.7 Eli Lilly: Peptide-based Drugs Portfolio
Table 6.8 FirstString Research: Key Highlights
Table 6.9 FirstString Research: Peptide-based Drugs Portfolio
Table 6.10 Novo Nordisk: Key Highlights
Table 6.11 Novo Nordisk: Peptide-based Drugs Portfolio
Table 6.12 Novo Nordisk: Recent Developments and Future Outlook
Table 6.13 Palatin Technologies: Key Highlights
Table 6.14 Palatin Technologies: Peptide-based Drugs Portfolio
Table 6.15 RegeneRx Biopharmaceuticals: Key Highlights
Table 6.16 RegeneRx Biopharmaceuticals: Peptide-based Drugs Portfolio
Table 6.17 RegeneRx Biopharmaceuticals: Recent Developments and Future Outlook
Table 6.18 Stealth BioTherapeutics: Key Highlights
Table 6.19 Stealth BioTherapeutics: Peptide-based Drugs Portfolio
Table 6.20 Stealth BioTherapeutics: Recent Developments and Future Outlook
Table 6.21 Takeda: Key Highlights
Table 6.22 Takeda: Peptide-based Drugs Portfolio
Table 6.23 Zealand Pharma: Key Highlights
Table 6.24 Zealand Pharma: Peptide-based Drugs Portfolio
Table 6.25 Zealand Pharma: Recent Developments and Future Outlook
Table 7.1 Partnerships and Collaborations: List of Peptide Therapeutics Initiatives Undertaken by Big
Pharma Players
Table 8.1 Peptide Therapeutics: List of Partnerships and Collaborations, 2015-2021
Table 9.1 Peptide Therapeutics: List of Funding and Investments, 2015-2021
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 12.1 Peptides and Macrocycle Drug Discovery: List of Service Providers
Table 12.2 Peptides and Macrocycle Drug Discovery Platform Providers: Information on Types of Peptide
Discovered
Table 12.3 Peptide Therapeutics: List of Contract Peptide API Manufacturers
Table 12.4 Peptide Therapeutics: List of Custom Peptide Manufacturers
Table 13.1 Peptide Therapeutics: List of Novel Peptide Therapeutics
Table 14.1 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Autoimmune Diseases
Table 14.2 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Cardiovascular Diseases
Table 14.3 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for CNS Diseases
Table 14.4 Value Creation Analysis: Information on Approved Peptide Therapeutics for Dermatological
Diseases
Table 14.5 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Endocrine Diseases
Table 14.6 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Gastrointestinal Diseases
Table 14.7 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Genetic Diseases
Table 14.8 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Hematological
Diseases
Table 14.9 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Infectious
Diseases
Table 14.10 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Inflammatory
Diseases
Table 14.11 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Metabolic Diseases
Table 14.12 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for
Oncological Diseases
Table 14.13 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Ophthalmic
Diseases
Table 14.14 Value Creation Analysis: Information on Approved and Clinical Stage Peptide for Other
Diseases
Table 17.1 Peptide Therapeutics: Distribution by Phase of Development
Table 17.2 Peptide Therapeutics: Distribution by Type of Peptide
Table 17.3 Peptide Therapeutics: Distribution by Route of Administration
Table 17.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
Table 17.5 Peptide Therapeutics: Distribution by Therapeutic Area
Table 17.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
Table 17.7 Peptide Therapeutics: Distribution by Route of Administration and Key Therapeutic Area
Table 17.8 Peptide Therapeutics Developers: Distribution by Year of Establishment
Table 17.9 Peptide Therapeutics Developers: Distribution by Company Size
Table 17.10 Peptide Therapeutics Developers: Distribution by Geography
Table 17.11 Peptide Therapeutics Developers: Key Players
Table 17.12 Peptide Therapeutics Developers: Distribution by Key Players and Phase of
Table 17.13 Eli Lilly: Annual Revenues, 2015-2020 (USD Million)
Table 17.14 Novo Nordisk: Annual Revenues, 2015-2020 (DKK Million)
Table 17.15 Palatin Technologies: Annual Revenues, 2015-2020 (USD Million)
Table 17.16 Takeda: Annual Revenues, 2015-2020 (JPY Million)
Table 17.17 Zealand Pharma: Annual Revenues, 2015-2020 (DKK Million)
Table 17.18 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.19 Partnerships and Collaborations: Distribution by Year of Partnership
Table 17.20 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.21 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.22 Partnerships and Collaborations: Distribution by Focus Area

25. 25
25
2021 © Roots Analysis
List of Tables (2/2)
Table 17.23 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
Table 17.24 Partnerships and Collaborations: Distribution by Type of Peptide
Table 17.25 Partnerships and Collaborations: Distribution by Route of Administration
Table 17.26 Partnerships and Collaborations: Distribution by Route of Administration and Geography
Table 17.27 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of
Development
Table 17.28 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.29 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 17.30 Most Active Players: Distribution by Number of Partnerships
Table 17.31 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 17.32 Partnerships and Collaborations: Local and International Agreements
Table 17.33 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances
Table 17.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested,
2015-2021 (USD Million)
Table 17.35 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2021
Table 17.36 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding,
2015-2021 (USD Million)
Table 17.37 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2015-2021
Table 17.38 Funding and Investment Analysis: Summary of Investments, 2015-2021 (USD Million)
Table 17.39 Funding and Investment Analysis: Distribution by Geography
Table 17.40 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 17.41 Most Active Players: Distribution by Number of Funding Instances
Table 17.42 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.43 Funding and Investment Analysis: Distribution by Type of Investors
Table 17.44 Funding and Investment Analysis: Distribution by Leading Investors
Table 17.45 Funding and Investment Analysis: Distribution of Instances by Phase of Development
Table 17.46 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 17.47 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2000-2021
Table 17.48 Clinical Trial Analysis: Distribution by Trial Status
Table 17.49 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.50 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 17.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year,
Pre 2000-2021
Table 17.52 Clinical Trial Analysis: Distribution by Study Design
Table 17.53 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.54 Most Active Players: Distribution by Number of Registered Trials
Table 17.55 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.56 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 17.57 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 17.58 Global Peptide Therapeutics Market, 2021-2030 (USD Billion)
Table 17.59 Peptide Therapeutics Market: Distribution by Type of Peptide, 2021-2030
Table 17.60 Peptide Therapeutics Market: Distribution by Route of Administration, 2021-2030
Table 17.61 Peptide Therapeutics Market: Distribution by Geography, 2021-2030
Table 17.62 Peptide Therapeutics Market: Distribution by Therapeutic Area, 2021-2030
Table 17.63 Peptide Therapeutics Market for Autoimmune Diseases, 2021-2030 (USD Billion)
Table 17.64 Peptide Therapeutics Market for Cardiovascular Diseases, 2021-2030 (USD Billion)
Table 17.65 Peptide Therapeutics Market for CNS Diseases, 2021-2030 (USD Billion)
Table 17.66 Peptide Therapeutics Market for Dermatological Diseases, 2021-2030 (USD Billion)
Table 17.67 Peptide Therapeutics Market for Endocrine Diseases, 2021-2030 (USD Billion)
Table 17.68 Peptide Therapeutics Market for Gastrointestinal Diseases, 2021-2030 (USD Billion)
Table 17.69 Peptide Therapeutics Market for Genetic Diseases, 2021-2030 (USD Billion)
Table 17.70 Peptide Therapeutics Market for Hematological Diseases, 2021-2030 (USD Billion)
Table 17.71 Peptide Therapeutics Market for Infectious Diseases, 2021-2030 (USD Billion)
Table 17.72 Peptide Therapeutics Market for Inflammatory Diseases, 2021-2030 (USD Billion)
Table 17.73 Peptide Therapeutics Market for Metabolic Diseases, 2021-2030 (USD Billion)
Table 17.74 Peptide Therapeutics Market for Oncological Diseases, 2021-2030 (USD Billion)
Table 17.75 Peptide Therapeutics Market for Ophthalmic Diseases, 2021-2030 (USD Billion)
Table 17.76 Peptide Therapeutics Market for Other Diseases, 2021-2030 (USD Billion)

26. 26
26
2021 © Roots Analysis
List of Companies and Organizations (1/3)
1. 13therapeutics
2. 7 Med Health Ventures
3. 9 Meters Biopharma
4. Abbott
5. Abingworth
6. Acorn Bioventures
7. ACT Capital Management
8. Adage Capital Management
9. Adams Street Partners
10. Advanced Accelerator Applications
11. Aileron Therapeutics
12. AJU IB Investment
13. Akashi Therapeutics
14. Alexion Pharmaceuticals
15. Allysta Pharmaceuticals
16. Alphabet venture arm
17. Altimmune
18. Amgen
19. Amolyt Pharma
20. Ampio Pharmaceuticals
21. Amyndas Pharmaceuticals
22. Andera Partners
23. Angiochem
24. Anji Pharmaceuticals
25. AOP Orphan Pharmaceuticals
26. Apellis Pharmaceuticals
27. Apeptico
28. APIM Therapeutics
29. Apitope
30. Aquestive Therapeutics
31. Arch Biopartners
32. ARCH Venture Partners
33. Arix Bioscience
34. Asahi Kasei
35. AsclepiX Therapeutics
36. Astellas Pharma
37. AstraZeneca
38. Atlas Venture
39. Atox Bio
40. Aurinia Pharmaceuticals
41. Avilex Pharma
42. Avion Pharmaceuticals
43. Barer & Son Capital
44. Bayer
45. Becker
46. Belfius
47. Bergens forskningsstiftelse
48. Beth Israel Deaconess Medical Center
49. Better Ventures
50. Bicycle Therapeutics
51. Biogenosis
52. Bioglan
53. BioLineRx
54. Biolingus
55. Biomarck Pharmaceuticals
56. BioMarin Pharmaceutical
57. Biomedical Advanced Research and Development
Authority (BARDA)
58. BiomedInvest
59. BioMedPartners
60. Bios Partners
61. Biosciences Research & Commercialization Center
62. BioSkin
63. BL&H
64. Boehringer Ingelheim
65. Boehringer Ingelheim Venture Fund
66. Boryung Pharmaceutical
67. Bossa Ventures
68. Boston Therapeutics
69. Bpifrance
70. Brightlands Life Sciences Ventures
71. Bristol Myers Squibb
72. Buttonwood
73. BVF Partners
74. Cambridge Innovation Capital (CIC)
75. Canaccord Genuity
76. CanBas
77. Cancer Research UK
78. Capital Community Angels
79. Cara Therapeutics
80. CARB-X (Combating Antibiotic Resistant Bacteria
Biopharmaceutical Accelerator)
81. Cardiorentis
82. Carmot Therapeutics
83. Catalent
84. Cathay Venture
85. Celgene
86. Cellastra
87. Cend Therapeutics
88. Chiasma Pharma
89. Chondropeptix
90. Chrysalis BioTherapeutics
91. Clinical Research Center for Hair and Skin
92. Clinuvel Pharmaceuticals
93. CohBar
94. Cold Spring Harbor Laboratory
95. Constant Therapeutics
96. Contura
97. Cormorant Asset Management
98. CureDM
99. Curonz
100. Cutanea Life Sciences
101. Cystic Fibrosis Foundation Therapeutics
102. Cytovation
103. Dana-Farber/Boston Children’s Cancer and Blood
Disorders Center
104. Deerfield Management
105. Diabetology
106. Diapin Therapeutics
107. E&Investment
108. Eczacibasi
109. Elan Pharmaceuticals
110. Eli Lilly
111. Endo Ventures
112. Entera Bio
113. Enteris BioPharma
114. Epidarex Capital
115. Epimede
116. Eshelman Ventures
117. Esperance Pharmaceuticals
118. European Commission
119. F2 Capital
120. F4 Pharma
121. Fannin Partners
122. Ferring Pharmaceuticals
123. First In Ventures
124. FirstString Research
125. Follicum
126. Foresite Capital
127. Founders Fund
128. Fountain Healthcare Partners
129. F-Prime Capital Partners
130. Frontier Biotechnologies
131. FUJIFILM Toyama Chemical
132. Genentech
133. Genervon Biopharmaceuticals
134. GeneScience
135. Genus Oncology
136. GF Ventures
137. Gila Therapeutics
138. GlaxoSmithKline
139. GlioCure
140. GlycoNet
141. Google Ventures
142. Government of Canada
143. Government of Quebec
144. Grand Oaks Capital
145. G-tree BNT
146. GYRUS Pharma
147. HBG Beteiligungs- und Beratungsgesellschaft
148. HealthCare Royalty Partners (HCR)
149. Healthlink Capital
150. Hercules Capital
151. Hestia Investments
152. HighTide Therapeutics
153. Hillhouse Capital Group
154. Horizon Technology Finance
155. Horizons Ventures
156. iBio
157. ILC Therapeutics
158. Imcyse
159. ImmuPharma
160. InCube Ventures
161. InFocus Capital Partners
162. InnoBio 2
163. Innovate UK
164. Inotrem
165. Integra Holdings
166. Inter-American Development Bank (IDB)
167. InterK Peptide Therapeutics
168. Intervest
169. Invest Michigan
170. Investinor
171. Invus
172. Ipsen
173. Issar Pharmaceuticals

27. 27
27
2021 © Roots Analysis
List of Companies and Organizations (2/3)
174. Janssen Biotech
175. Janssen Pharmaceuticals
176. JDRF
177. Jennison Associates
178. Johnson & Johnson
179. Kairos Ventures
180. Kaitai Capital
181. Kalos Therapeutics
182. KeyBioscience
183. Knoll Capital Management
184. KPC Pharmaceuticals
185. Kreos Capital
186. KU Leuven
187. Kurma Partners
188. L1 Capital Global Opportunities Master Fund
189. La Jolla Pharmaceutical
190. Lanstead Capital
191. Lassogen
192. Lincoln Park Capital Fund
193. Lind Global Macro Fund
194. LipimetiX Development
195. Live Like Bella® Foundation
196. Longevity Biotech
197. Longwood Fund
198. Lonza
199. LRM Funds
200. LSP
201. Lundbeckfonden Ventures
202. Madryn Asset Management
203. Maven Investment Partners
204. Maxim Group
205. MEDARVA Foundation
206. MedImmune
207. Mediolanum Farmaceutici
208. Megapharm
209. MElkin Pharmaceuticals
210. Merck
211. Merck Sharp & Dohme (MSD)
212. MeSCue-Janusys
213. Michigan Capital Network Venture Fund III
214. Mitsubishi Tanabe Pharma
215. Morningside Ventures
216. MPM Capital
217. Nan Fung Technology’s Pivotal Beta
218. Nanomerics
219. National Cancer Institute (NCI)
220. National Eye Institute (NEI)
221. National Heart, Lung, and Blood Institute (NHLBI)
222. National Institute of Allergy and Infectious
Diseases
223. National Institute of Dental and Craniofacial
Research (NIDCR)
224. National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK)
225. National Institutes of Health (NIH)
226. National Multiple Sclerosis Society
227. National Research Council Canada
228. Neuro-Bio
229. NeuroRx
230. New Enterprise Associates
231. NextPharma
232. NoNO
233. Noshaq
234. NovaCell Technology
235. Novartis
236. Novartis Venture Fund
237. Novo Nordisk
238. Novo Ventures
239. NV Industriebank LIOF
240. Oncology Pharma
241. Oncopeptides
242. ONL Therapeutics
243. Onyx Therapeutics
244. OPKO Health
245. Oramed Pharmaceuticals
246. OrbiMed
247. Otsuka Pharmaceutical
248. Ovoca Bio
249. Oxalo Therapeutics
250. Oxurion
251. PAION
252. Palatin Technologies
253. Park West Asset Management
254. Partners Innovation Fund
255. PEP-Therapy
256. PeptiDream
257. Peptilogics
258. Peptron
259. Perceptive Xontogeny Venture Fund
260. Pfizer
261. Pfizer Venture Investments
262. Pharma Research Products
263. PharmaMar
264. Pharmstandard International
265. Piedmont Capital Partners
266. PIN Pharma
267. Ping An Ventures
268. Pint Pharma
269. Playground Global
270. PMV
271. Polyphor
272. Pontifax
273. Praxis Pharmaceutical
274. Presight Capital
275. Priavoid
276. proDERM
277. ProLynx
278. ProMore Pharma
279. ProNeurogen
280. Protagonist Therapeutics
281. Protagenic Therapeutics
282. Proteimax
283. PSQ Capital
284. Pulmotect
285. Qilu Pharmaceutical
286. Quaker Partners
287. Quantum Leap Healthcare Collaborative (QLHC)
288. Quartesian
289. Radius Health
290. Rani Therapeutics
291. Rapha Capital Management
292. RegeneRx Biopharmaceuticals
293. ReGenTree
294. ReumaNederland
295. Rhythm Pharmaceuticals
296. Riesner Verwaltungs
297. Roche
298. Rock Springs Capital Management
299. Salem Partners
300. Salix Pharmaceuticals
301. Sanofi
302. Sanofi-Aventis
303. Santhera Pharmaceuticals
304. Sapience Therapeutics
305. Sarsia Seed
306. Satter Medical Technology Partners
307. SciClone Pharmaceuticals
308. Scios (Acquired by Johnson & Johnson)
309. Seachaid Pharmaceuticals
310. Sectoral Asset Management
311. Serpin Pharma
312. Seventure Partners
313. SFJ Pharmaceuticals
314. Shanghai Fosun Pharmaceutical
315. Shire
316. SIRS Therapeutics
317. Société Fédérale de Participations et
d'Investissement (SFPI)
318. Société Régionale d'Investissement de Wallonie
(SRIW)
319. Sofinnova Ventures
320. Soligenix
321. Sophos Capital
322. Soricimed Biopharma
323. Specialised Therapeutics
324. SR One
325. Stealth BioTherapeutics
326. SV Health Investors
327. Swedish Orphan Biovitrum (SOBI)
328. SYNG Pharmaceuticals
329. TaiAn Technologies
330. Takeda
331. Tarsa Therapeutics
332. TearSolutions
333. Technomark Life Sciences
334. TEDCO
335. Televenture (Funded through NIK III)
336. Texas A&M University Health Science Center
337. The Column Group
338. The Leona M. and Harry B. Helmsley Charitable
Trust
339. University of Bath
340. The University of Chicago Innovation Fund
341. The University of Texas MD Anderson Cancer
Center
342. TheraSource

28. 28
28
2021 © Roots Analysis
List of Companies and Organizations (3/3)
343. Theratechnologies
344. Third Rock Ventures
345. Topas Therapeutics
346. Tsingyuan Ventures
347. TTY Biopharm
348. TwoToBiotech
349. UCB Pharma
350. University of Freiburg
351. University of Missouri Research Reactor (MURR®)
352. University of St Andrews
353. US Department of Defense
354. UVA Seed Fund
355. ValiRx
356. Vault Pharma
357. Vaxeal
358. venBio Global Strategic Fund
359. Ventac Partners
360. VentureHealth
361. Vertex Ventures
362. Vesalius Biocapital
363. Viatem
364. Vifor Pharma
365. Vinnova
366. Virtus Inspire Ventures
367. Vivo Capital
368. VTC Innovation Fund
369. Wales Life Sciences Fund
370. West Midlands Academic Health Science Network
(WMAHSN)
371. WuXi AppTec
372. Wyvern
373. Xigen
374. YuYang D&U
375. Zealand Pharma
376. Zucara Therapeutics

29. 29
29
2021 © Roots Analysis
Other Recent Offerings

30. 30
30
2021 © Roots Analysis
We provide deep expertise, experience and knowledge in bio-pharmaceutical and allied
markets
Markets
Capabilities
Example Markets
Diagnostics
Emerging technologies
Medical devices
Therapeutic areas
Drug delivery
Clinical trials
Health & wellness
Pharmaceutical
packaging
Example Capabilities
Market landscaping
Competitive analysis
‘Value chain’ analysis
Financial and business
planning
Technology / product
benchmarking
Drug pipeline evaluation
Company profiling
About Roots Analysis

31. 31
31
2021 © Roots Analysis
The leading research house for professionals, analysts
and researchers for unbiased and insightful opinions
For a truly global perspective
www.rootsanalysis.com
For more details, write to us
Sales / Subscriptions: sales@rootsanalysis.com
Other Queries: enquiry@rootsanalysis.com